Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Assets (2016 - 2025)

Arrowhead Pharmaceuticals' Assets history spans 16 years, with the latest figure at $1.6 billion for Q4 2025.

  • For Q4 2025, Assets rose 58.25% year-over-year to $1.6 billion; the TTM value through Dec 2025 reached $1.6 billion, up 58.25%, while the annual FY2025 figure was $1.4 billion, 21.54% up from the prior year.
  • Assets reached $1.6 billion in Q4 2025 per ARWR's latest filing, up from $1.4 billion in the prior quarter.
  • In the past five years, Assets ranged from a high of $1.6 billion in Q4 2025 to a low of $626.3 million in Q4 2023.
  • Average Assets over 5 years is $944.7 million, with a median of $839.8 million recorded in 2023.
  • Peak YoY movement for Assets: decreased 29.75% in 2023, then surged 64.74% in 2025.
  • A 5-year view of Assets shows it stood at $638.5 million in 2021, then soared by 39.61% to $891.5 million in 2022, then fell by 29.75% to $626.3 million in 2023, then surged by 61.86% to $1.0 billion in 2024, then surged by 58.25% to $1.6 billion in 2025.
  • Per Business Quant, the three most recent readings for ARWR's Assets are $1.6 billion (Q4 2025), $1.4 billion (Q3 2025), and $1.4 billion (Q2 2025).